BRPI0508320A - derivados de beta-aminoácido como inibidores do fator xa - Google Patents

derivados de beta-aminoácido como inibidores do fator xa

Info

Publication number
BRPI0508320A
BRPI0508320A BRPI0508320-6A BRPI0508320A BRPI0508320A BR PI0508320 A BRPI0508320 A BR PI0508320A BR PI0508320 A BRPI0508320 A BR PI0508320A BR PI0508320 A BRPI0508320 A BR PI0508320A
Authority
BR
Brazil
Prior art keywords
factor
compounds
inhibitors
formula
amino acid
Prior art date
Application number
BRPI0508320-6A
Other languages
English (en)
Inventor
Matthias Urmann
Marc Nazare
Volkmar Wehner
Hans Matter
Armin Bauer
Michael Wagner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0508320A publication Critical patent/BRPI0508320A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33—Two oxygen atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE BETA-AMINOáCIDO COMO INIBIDORES DO FATOR Xa. A presente invenção refere-se a compostos da fórmula I, em que R¬ 0¬; R¬ 1¬; R¬ 2¬; R¬ 3¬; R¬ 4¬; R¬ 5¬; R¬ 6¬; Q; V, G e M têm os significados indicados nas reivindicações. Os compostos da fórmula I são compostos farmacologicamente ativos valiosos. Eles exibem um efeito antitrombótico forte e são adequados, por exemplo, para a terapia e profilaxia de distúrbios cárdiovasculares como doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis do fator Xa (FXa) e/ou fator VIIa (FVIIa) das enzimas de coagulação sanguínea, e podem em geral ser aplicados em condições em que uma atividade indesejada do fator Xa e/ou fator VIIa está presente ou para a cura ou prevenção de que uma inibição do fator Xa e/ou fator VIIa é pretendida. A invenção além disso refere-se aos processos para a preparação de compostos da fórmula I, seu uso, en particular como ingredientes ativos em produtos farmacêuticas compreendendo-os.
BRPI0508320-6A 2004-03-03 2005-02-19 derivados de beta-aminoácido como inibidores do fator xa BRPI0508320A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004904A EP1571154A1 (en) 2004-03-03 2004-03-03 Beta-aminoacid-derivatives as factor Xa inhibitors
PCT/EP2005/001736 WO2005095440A1 (en) 2004-03-03 2005-02-19 BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BRPI0508320A true BRPI0508320A (pt) 2007-07-24

Family

ID=34745988

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508320-6A BRPI0508320A (pt) 2004-03-03 2005-02-19 derivados de beta-aminoácido como inibidores do fator xa

Country Status (15)

Country Link
US (1) US20070179122A1 (pt)
EP (2) EP1571154A1 (pt)
JP (1) JP2007535497A (pt)
KR (1) KR20060122950A (pt)
CN (1) CN1926148A (pt)
AU (1) AU2005229320A1 (pt)
BR (1) BRPI0508320A (pt)
CA (1) CA2559948A1 (pt)
GT (1) GT200500026A (pt)
IL (1) IL177470A0 (pt)
PA (1) PA8624901A1 (pt)
PE (1) PE20051160A1 (pt)
TW (1) TW200540187A (pt)
UY (1) UY28787A1 (pt)
WO (1) WO2005095440A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
DE102004062544A1 (de) * 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
JP2014501790A (ja) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノンの調製方法及びイソキノリノンの固体形態
WO2013031930A1 (ja) * 2011-08-31 2013-03-07 味の素株式会社 イミン誘導体
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6293770B2 (ja) 2012-11-05 2018-03-14 ナント ホールディングス アイピー，エルエルシー ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CN104311537B (zh) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675689B2 (en) * 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JP2003500386A (ja) * 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
AU5283900A (en) * 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
AU1770001A (en) * 1999-11-24 2001-06-04 Cor Therapeutics, Inc. Beta-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factorxa
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10050723A1 (de) * 2000-10-13 2002-04-25 Merck Patent Gmbh N-Substituierte Aminosäurederivate (Faktor Xa Inhibitoren 12)
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE10102322A1 (de) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7741341B2 (en) * 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
CA2559948A1 (en) 2005-10-13
PA8624901A1 (es) 2005-09-28
PE20051160A1 (es) 2006-02-07
UY28787A1 (es) 2005-09-30
EP1723164A1 (en) 2006-11-22
GT200500026A (es) 2006-06-09
US20070179122A1 (en) 2007-08-02
JP2007535497A (ja) 2007-12-06
IL177470A0 (en) 2006-12-10
KR20060122950A (ko) 2006-11-30
WO2005095440A1 (en) 2005-10-13
CN1926148A (zh) 2007-03-07
EP1571154A1 (en) 2005-09-07
TW200540187A (en) 2005-12-16
AU2005229320A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
CL2004001080A1 (es) COMPUESTOS DERIVADOS DE INDAZOL, INHIBIDORES DEL FACTOR Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA Y OTRAS.
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
BR0011461A (pt) Inibidores do fator viia
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
DE602004013577D1 (de) TRIAZOLDERIVATE ALS FAKTOR-Xa-INHIBITOREN
ECSP056179A (es) Derivados de azaindol como inhibidores del factor xa
DOP2006000119A (es) Derivados de (sulfamoil-alquil)-amida de ácido heteroaril-carboxílico como inhibidores del factor xa
BR112014028189A2 (pt) derivados de benzo[1,3]dioxina e seu uso como antagonistas de lpar5
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.